Despite the available evidence being quite limited and the included papers reporting different approaches to calculate the detection rate, all the authors investigating the accuracy of PET/CT with PSMA-targeting radiopharmaceuticals in ccRCC patients stated excellent performances both in per-patient- and per-lesion-based analyses in newly diagnosed patients as well as previously treated patients undergoing disease restaging without significant differences among the explored clinical settings [29,30,31,32,40]. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.